Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -80.0%
- Operating Margin Trend +53.92 pp/yr
XERS
Xeris Biopharma Holdings, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -487.9%
- 5yr Share-Count CAGR 21.6%
Growth Quality
Weight: 35%
B
72
- 5yr Revenue CAGR 55.8%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
D-
29
- 5yr FCF Margin -68.3%
- 5yr FCF/NI Conversion 50.42x
Balance Sheet
Weight: 10%
C-
48
- Net Debt / EBITDA -5.77x
- Interest Coverage (EBIT/Int) 0.02x
- Altman Z-Score 0.78
Stability
Weight: 5%
A+
93
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 7
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 3 gurus held; 2 added; 1 full exit.
- Holders
- 2 -1
- Avg Δ position
- +12.5%
- New buys
- 0
- Full exits
- 1
- Wood sold -100%
- Greenblatt increased +22%
- Cooperman increased +3%